HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Temozolomide in the treatment of children with newly diagnosed diffuse intrinsic pontine gliomas: a report from the Children's Oncology Group.

Abstract
An open-label phase II study (ACNS0126) testing the efficacy of chemoradiotherapy with temozolomide (TMZ) followed by adjuvant TMZ was conducted by the Children's Oncology Group. During the period from July 6, 2004 through September 6, 2005, 63 children with newly diagnosed diffuse intrinsic pontine glioma (DIPG) were enrolled in the study. All patients received TMZ at a dosage of 90 mg/m(2)/day for 42 days to a dose of 59.4 Gy. Four weeks following irradiation, TMZ was given at a dosage of 200 mg/m(2)/day for 5 days every 28 days, for a total of 10 cycles. The primary objective of the statistical analysis was to determine whether the current treatment produced a 1-year event-free survival (EFS) rate higher than the historical baseline of 21.9% observed in CCG-9941. The mean 1-year EFS (± standard deviation) was 14% ± 4.5%, compared with 21.9% ± 5% for CCG-9941. The P value of the test of comparison of 1-year EFS, based on a 1-sided, 1-sample test of proportions, was .96. There was no evidence that temozolomide produced a 1-year EFS rate higher than 21.9%. The mean 1-year OS (± standard deviation) was 40% ± 6.5%, compared with 32% ± 6% for CCG-9941. The median time to death was 9.6 months. Chemoradiotherapy with TMZ followed by adjuvant TMZ is not more effective than previously reported regimens for the treatment of children with DIPG.
AuthorsKenneth J Cohen, Richard L Heideman, Tianni Zhou, Emiko J Holmes, Robert S Lavey, Eric Bouffet, Ian F Pollack
JournalNeuro-oncology (Neuro Oncol) Vol. 13 Issue 4 Pg. 410-6 (Apr 2011) ISSN: 1523-5866 [Electronic] England
PMID21345842 (Publication Type: Clinical Trial, Phase II, Journal Article, Research Support, N.I.H., Extramural)
Chemical References
  • Antineoplastic Agents, Alkylating
  • Dacarbazine
  • Temozolomide
Topics
  • Adolescent
  • Antineoplastic Agents, Alkylating (therapeutic use)
  • Brain Stem Neoplasms (drug therapy, radiotherapy)
  • Chemotherapy, Adjuvant
  • Child
  • Child, Preschool
  • Combined Modality Therapy
  • Dacarbazine (analogs & derivatives, therapeutic use)
  • Female
  • Humans
  • Male
  • Pons
  • Radiotherapy Dosage
  • Survival Rate
  • Temozolomide
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: